The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & AcquisitionsMediumUpdated×2•Originally published 22 April 2026•Updated 23 April 2026•

1 min read

Amneal Pharmaceuticals to Acquire Kashiv BioSciences to Bolster Biosimilars Leadership

Key Facts

1Kashiv BioSciences has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals (NASDAQ: AMRX).

2The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.

about 1 month ago

Version History

Version 2about 1 month ago

What changed: Added strong preliminary Q1 financial results and an upward revision to the 2026 EPS guidance.

Version 1about 1 month ago

What changed: The story was updated to include the $1.1 billion deal valuation and the cash-and-stock transaction structure.

Amneal Pharmaceuticals (NASDAQ: AMRX) has entered into a definitive agreement to acquire Kashiv BioSciences for approximately $1.1 billion to establish a global leader in biosimilars. Alongside this strategic move, the company announced strong preliminary results for the first quarter, signaling robust operational momentum. Consequently, Amneal has raised its 2026 earnings per share (EPS) guidance, reflecting confidence in its long-term growth trajectory. The acquisition, expected to close in the second half of 2026, aims to integrate Kashiv’s development expertise with Amneal’s commercial scale. Analysts suggest that the upward revision in earnings guidance provides a positive backdrop for the integration process. The transaction remains subject to customary regulatory approvals and shareholder consent.